GGrantIndex
← Search

MONOCLONAL ANTIBODY MUJ591 PATIENTS W/ HORMONE INDEPENDANT PROSTATE CANCER

$79,525M01FY2000RRNIH

Weill Medical College Of Cornell Univ, New York NY

Investigators

Linked publications & trials

Abstract

Several characteristics of monoclonal antibodies (mAbs) are particularly well suited for the demands of prostate cancer therapy. muJ591 binds specifically with a prostate-related surface antigen. The investigators wish to define the toxicity and preliminary efficacy of mAb muJ591 in patients with hormone-independent prostate cancer.

View original record on NIH RePORTER →